ClinicalTrials.gg
RecruitingNCT05745181Updated Feb 27, 2023

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

A Phase 2 interventional study of CAR-T Cell Infusion in Acute T-lymphoblastic Leukemia and Acute T-lymphoblastic Lymphoma, sponsored by The Affiliated Hospital of Xuzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-27.

Sponsored by The Affiliated Hospital of Xuzhou Medical University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 6 open to participants now, 8 under way, none of them phase 3. Chimeric Antigen Receptor T-cells · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
5th of 10
20 · median 19
Started
2023
the only one that year
Phase 2
Only one
of the 10
Registered
6th of 10
by date
Lead sponsor
1 of 10
The Affiliated Hospital of Xuzhou Medical University

Among the 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 5th largest by planned enrollment, is the only one that started in 2023, is the only one in phase 2, and was the 6th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

6 of the 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About Chimeric Antigen Receptor T-cells

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of anti-CD1a CAR-T in the treatment of relapsed refractory acute T-lymphoblastic leukemia/lymphoblastic lymphoma.

Read the detailed description

Acute T-lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) is a highly heterogeneous hematological malignancy usually associated with genetic alterations/mutations in transcription factors that are major regulators of hematopoietic stem/progenitor cell homeostasis and T cell development. 70% of patients develop mass with myeloid invasion and other leukemia symptoms.

CD1a, a transfer membrane glycoprotein, is a cell surface antigen present on cortical T-ALL cells. It is present in 40% of T-ALL cases. Specific expression of this antigen has also been observed in developing cortical thymus cells. It was also slightly expressed in langerhans cells, digital dendritic cells, B lymphocytes and gastrointestinal epithelial cells. CD1a4 was not expressed in CD34+ progenitor cells or T cells during ontogeny. This property of CD1a makes it a suitable target antigen whose targeting minimizes the possibility of non-tumor toxicity.

This study intends to treat r/r CD1a+T-ALL/LBL with CD1a CAR-T to observe its safety and efficacy.

03

Conditions studied

  • Acute T-lymphoblastic Leukemia
  • Acute T-lymphoblastic Lymphoma

Keywords

  • anti-CD1a CAR-T
  • relapsed refractory
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients or their legal guardians voluntarily participate and sign the ; 2. Male or female patients aged 18-70 years (including 18 and 70 years); 3. The patient was diagnosed with CD1a+ acute T lymphoblastic leukemia/lymphoblastic lymphoma by pathology or flow cytometry, and had no effective treatment options at present, such as chemotherapy or hematopoietic stem cell transplantation after recurrence; Alternatively, the patient voluntarily chooses to administer antiCD1a-CAR T cells as salvage therapy. Inclusion criteria
  1. Patients or their legal guardians voluntarily participate and sign the informed consent;
  2. Male or female patients aged 18-70 years (including 18 and 70 years);
  3. The patient was diagnosed with CD1a+ acute T lymphoblastic leukemia/lymphoblastic lymphoma by pathology or flow cytometry, and had no effective treatment options at present, such as chemotherapy or hematopoietic stem cell transplantation after recurrence; Alternatively, the patient voluntarily chooses to administer antiCD1A-CAR T cells as salvage therapy.
  4. The following two categories are included:

(1) CD1a+T lymphoblastic lymphoma (T-LBL); (2) CD1a+ acute T-lymphoblastic leukemia (T-ALL). 5. Subject:

  1. There was no remission or residual lesions after treatment, and (auto/allo-HSCT) was not suitable;
  2. Relapse occurred after CR, and HSCT (auto/allo-HSCT) was not suitable;
  3. Patients with high risk factors;
  4. Relapse or no remission after hematopoietic stem cell transplantation or cellular immunotherapy.
  1. Measurable or evaluable lesions; 7. The patient's main tissues and organs function well:
  1. Liver function: /AST \< 3 times the (ULN) and total ≤34.2μmol/L;
  2. Renal function: creatinine \< 220 μmol/L;
  3. Lung function: indoor oxygen saturation ≥95%;
  4. Cardiac function: (LVEF) ≥40%. 8. The patients had not received any anti-cancer treatment such as chemotherapy, radiotherapy, immunotherapy (such as drugs) within the first 4 weeks of enrollment, and their previous treatment-related toxic reactions had recovered to ≤ grade 1 at the time of enrollment (except low toxicity such as hair loss); 9. The patient's peripheral shallow venous blood flow is smooth, which can meet the needs of intravenous infusion; 10. Patients with score ≤2 and expected survival time ≥3 months. 4. The following two categories are included:

(1) CD1a+T lymphoblastic lymphoma (T-LBL); (2) CD1a+ acute T-lymphoblastic leukemia (T-ALL). 5. Subject:

  1. There was no remission or residual lesions after treatment, and HSCT (auto/allo-HSCT) was not suitable;
  2. Relapse occurred after CR, and HSCT (auto/allo-HSCT) was not suitable;
  3. Patients with high risk factors;
  4. Relapse or no remission after hematopoietic stem cell transplantation or cellular immunotherapy.
  1. Measurable or evaluable lesions; 7. The patient's main tissues and organs function well:
  1. Liver function: ALT/AST \< 3 times the upper limit of normal (ULN) and total bilirubin ≤34.2μmol/L;
  2. Renal function: creatinine \< 220 μmol/L;
  3. Lung function: indoor oxygen saturation ≥95%;
  4. Cardiac function: left ventricular ejection fraction (LVEF) ≥40%. 8. The patients had not received any anti-cancer treatment such as chemotherapy, radiotherapy, immunotherapy (such as immunosuppressive drugs) within the first 4 weeks of enrollment, and their previous treatment-related toxic reactions had recovered to ≤ grade 1 at the time of enrollment (except low toxicity such as hair loss); 9. The patient's peripheral shallow venous blood flow is smooth, which can meet the needs of intravenous infusion; 10. Patients with ECOG score ≤2 and expected survival time ≥3 months.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant (urine/blood pregnancy test positive) or breastfeeding;
  2. Men or women who have planned to become pregnant within the last 1 year;
  3. The patients were not guaranteed to take effective measures (condoms or contraceptives, etc.) within 1 year after enrollment;
  4. Patients had uncontrollable infectious diseases within 4 weeks prior to enrollment;
  5. Active /C virus;
  6. Hiv-infected patients;
  7. Suffering from a serious disease or immunodeficiency disease;
  8. The patient is allergic to antibodies, cytokines and other macromolecular biological drugs;
  9. The patient had participated in other clinical trials within 6 weeks prior to enrollment;
  10. Systemic use of hormones within 4 weeks prior to enrollment (except for inhaled hormones);
  11. Suffers from mental illness;
  12. The patient has substance abuse/addiction;
  13. According to the researchers judgment, the patient had other conditions that were not suitable for inclusion.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    CAR-T Cell Infusion

    Peripheral blood mononuclear cells were isolated, amplified and cultured in vitro, pretreated with FC regimen, and Anti-CD1a CAR-T cells were transfused.

    Biological: CAR-T Cell Infusion

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate

    CR+PR

    Time frame: From 2 weeks to 1 year.

  2. Progression-free survival

    The time between treatment and observation of disease progression or death from any cause.

    Time frame: From 2 weeks to 1 year.

  3. overall survival

    The time interval between patient infusion of CAR-T and death from any cause or the end of follow-up.

    Time frame: From 2 weeks to 1 year.

  4. Event-free survival

    The time from the start of CAR-T infusion to the occurrence of any event.

    Time frame: From 2 weeks to 1 year.

Secondary outcomes

  1. Characterization of the level of CAR T cell expansion in subjects over time

    Characterization of the level of CAR T cell expansion in subjects over time.

    Time frame: From 2 weeks to 1 year.

  2. Duration of CAR T cells in subjects

    Duration of CAR T cells in subjects

    Time frame: From 2 weeks to 1 year.

  3. Characteristics of lymphocyte reduction in subjects

    Characteristics of lymphocyte reduction in subjects

    Time frame: From 2 weeks to 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jan 2026, 35 months after the start.

Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 35 months is below that.

Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Feb 27, 2023
StartActual
Feb 1, 2023
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jan 1, 2026
Last update
Feb 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05745181
Lead sponsor
The Affiliated Hospital of Xuzhou Medical University
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Feb 1, 2023
Primary completion
Jan 1, 2026 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Feb 27, 2023

Study contacts

Wei Sang, M.D., Ph.D.
Contact
xyfylbl515@xzhmu.edu.cn
13645207648

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chimeric Antigen Receptor T-cells

Start the discussion